- Home
- SKIL vs ATOS Comparison
SKIL vs ATOS Comparison
Compare SKIL & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIL
- ATOS
- Stock Information
- Founded
- SKIL 1998
- ATOS 2009
- Country
- SKIL United States
- ATOS United States
- Employees
- SKIL N/A
- ATOS N/A
- Industry
- SKIL Computer Software: Prepackaged Software
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- SKIL Technology
- ATOS Health Care
- Exchange
- SKIL Nasdaq
- ATOS Nasdaq
- Market Cap
- SKIL 123.2M
- ATOS 107.2M
- IPO Year
- SKIL N/A
- ATOS 2012
- Fundamental
- Price
- SKIL $15.40
- ATOS $0.77
- Analyst Decision
- SKIL
- ATOS Strong Buy
- Analyst Count
- SKIL 0
- ATOS 3
- Target Price
- SKIL N/A
- ATOS $6.17
- AVG Volume (30 Days)
- SKIL 22.8K
- ATOS 551.3K
- Earning Date
- SKIL 09-09-2025
- ATOS 08-12-2025
- Dividend Yield
- SKIL N/A
- ATOS N/A
- EPS Growth
- SKIL N/A
- ATOS N/A
- EPS
- SKIL N/A
- ATOS N/A
- Revenue
- SKIL $527,402,000.00
- ATOS N/A
- Revenue This Year
- SKIL $3.18
- ATOS N/A
- Revenue Next Year
- SKIL $2.50
- ATOS N/A
- P/E Ratio
- SKIL N/A
- ATOS N/A
- Revenue Growth
- SKIL N/A
- ATOS N/A
- 52 Week Low
- SKIL $11.87
- ATOS $0.55
- 52 Week High
- SKIL $34.43
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- SKIL 52.40
- ATOS 45.41
- Support Level
- SKIL $14.30
- ATOS $0.81
- Resistance Level
- SKIL $16.25
- ATOS $0.80
- Average True Range (ATR)
- SKIL 0.63
- ATOS 0.03
- MACD
- SKIL 0.13
- ATOS 0.00
- Stochastic Oscillator
- SKIL 61.26
- ATOS 50.86
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experience learner platform that serves learners world-wide. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.